New research - Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12Cmutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky

Compared to other KRAS inhibitors (sotorasib, adagrasib), glecirasib showed lower GI toxicity (diarrhea: 3.4% vs. 31-70% in others), potentially improving patient adherence.

The phase 3 trial (NCT06416410) combining glecirasib with SHP2 inhibitor JAB-3312 is underway!

#Onco404 #MedSky #OncSky

The authors included RRIDs in their Cancer Research Communications paper! Thanks for making your methods matter! #STMpublishing #RRID #STMpublishing

Results from a phase 2b trial of glecirasib, a novel KRAS G12C inhibitor, show promise for advanced/metastatic NSCLC patients with KRAS G12C mutations!

@naturemedicine.bsky.social @natureportfolio.nature.com

#Onco404 #Oncology #Cancer #NSCLC #TargetedTherapy #ClinicalTrials #MedSky #OncSky #lcsm

Feed: "Clinical Trials Arena"
By: Annabel Kartal Allen on Monday, December 1, 2025

Here’s another toxic KRAS inhibitor that doesn’t look like the « Holy Grail » of oncology drug discovery. More than 50 inhibitors now competing. Economics of that?

www.nature.com/articles/s41...

Jacobio Pharma Reports Strong Growth and Breakthroughs in Interim Results for 2025#China#Beijing#cancer_therapy#Jacobio_Pharma#glecirasib

Jacobio Pharma Reports Impressive Annual Revenue Growth For 2024#China#Beijing#Jacobio_Pharma#R&D#glecirasib

❇️ Glecirasib plus sitneprotafib in patients with KRASG12C mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial tinyurl.com/yx5864j9

Out now in Nature Medicine:

In a single-arm phase 2b trial, Glecirasib, an oral KRAS-G12C inhibitor, had an overall response rate of 47.9% in patients with locally advanced or metastatic KRAS-G12C-mutated NSCLC.

rdcu.be/d5Nnt

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

www.viv-media.com/infozx-35584...

Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism 2 with cetuximab or SHP2 inhibitor JAB-3312 https://covalentmodifiers.blogspot.com/2025/05/glecirasib-potent-and-selective.html

Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism 2 with cetuximab or SHP2 inhibitor JAB-3312 https://covalentmodifiers.blogspot.com/2025/05/glecirasib-potent-and-selective.html

Glecirasib, a potent and selective covalent KRAS G12C inhibitor exhibiting synergism 2 with cetuximab or SHP2 inhibitor JAB-3312 https://covalentmodifiers.blogspot.com/2025/05/glecirasib-potent-and-selective.html

5 innovadores medicamentos chinos, incluyendo inhibidores de:
🧬 KRAS G12C
🧬 EGFR de tercera generación
🧬 EGFR exon 20

#Fulzerasib #Sunvozertinib #Limertinib #Glecirasib #Garsorasib #Cáncer #Oncología #TerapiaDirigida #InnovaciónMédica #KRAS
#KRASG12C #EGFR #EGFRexon20 #DengYueMedicinasEnHongKong

💊 Glecirasib Citrate Tablets—now approved in China!
🎯 Targets KRAS G12C–mutated advanced NSCLC

📎 Learn more: dengyuemed.com/product/airu...
📧 info@dengyuemed.com

#GlecirasibCitrateTablets #Allist #KRASG12C #KRAS #KRASInhibitor #NSCLC #LungCancerTreatment
#HongKongDengYueMedicine